

## ASX Announcement (ASX: HLS)

ASX Limited  
Market Announcements Office  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney NSW 2000



ACN 064 530 516  
REGISTERED OFFICE:  
LEVEL 6  
203 PACIFIC HIGHWAY  
ST LEONARDS NSW 2065  
TEL: +61 2 9432 9400  
healius.com.au

3 June 2022

### Healius: FY2022 YTD update and Adora Fertility completion

Healius Limited (ASX:HLS) issued a trading update on 20 May 2022 as part of its Investor Day which included the following:

Core Businesses:

- Q3 Pathology slightly ahead of Medicare data (as in the first half) and Imaging also slightly ahead
- Operational challenges and additional costs due to level of COVID infections e.g. staff on sick leave, last-minute cancellations of surgery and imaging procedures

COVID-19 Pathology:

- After a strong January, COVID testing around 15k per working day through February to April (as expected at 1H22 results)

#### April market trends

Following the release of Medicare data for April, the market data for the 4 months to 30 April 2022 is:

- Core pathology benefits -8.8% on pcp, compared to -1.4% in 1H 2022<sup>1</sup>
- Imaging benefits -8.2% on pcp, compared to +0.6% in 1H 2022<sup>2</sup>

#### HLS trading update

The Company has continued to trade broadly in line with its aforementioned update, including trading slightly ahead of Medicare in its core businesses and COVID testing remaining around 15,000 per working day in May. It has also continued to experience the effects of high levels of COVID infections in its workforce and patient and clinician cohorts.

Given ongoing market volatility and the range of broker forecasts, Healius announces that its unaudited underlying EBIT for the year-to-date to May 2022 is in the order of \$473 million, with strong trading in the first half but more difficult market conditions in the second half of the financial year. This represents an increase of over 100% on the unaudited underlying EBIT of \$234 million for the same period in FY 2021.

---

<sup>1</sup> Core Pathology = Pathology Benefits paid for items P1-P9 excluding COVID items

<sup>2</sup> Imaging = Category 5, Diagnostic Imaging Benefits paid

## **HLS strategy update**

The Company continues to advance its portfolio simplification as a diagnostics operator and is pleased to announce the completion of the sale of Adora Fertility this week.

As noted in its Investor Day, Healius has refinanced its debt facilities, commenced a second buy-back and reconfirmed its margin expansion targets from its Sustainable Improvement Program.

The Company remains focussed on growing its core pathology and imaging businesses, where it is well-positioned as an incumbent operator with operating leverage, and on growing its emerging diagnostic positions, underpinned by its market-leading digital program.

Healius will announce its full audited results for FY 2022 on 31 August 2022.

**ENDS**

For further information contact:

Janet Payne  
Group Executive, Corporate Affairs  
Mobile: +61 409 995 517

Charlene Jaw  
Manager, Corporate Affairs  
Mobile: +61 403 222 810

*For over 30 years Healius has been one of Australia's leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has three businesses, pathology, imaging and day hospitals. Through its unique footprint of centres and its 11,000 employees, Healius provides specialty diagnostic services to consumers and their referring practitioners, as well as enabling independent healthcare professionals to deliver care in its day hospitals.*

The release of this announcement has been authorised by the Disclosure Committee.